Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beryl DrugsBOM:524606 +7.85%68 Interest Coverage is 13.11 as of Mar. 2026, which is 391% above its 10-year median of 2.67. GuruFocus rates BOM:524606 with a GF Score™ of 68/100 and a GF Value™ of ₹20.66 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 684 Drug Manufacturers companies, Beryl Drugs ranks worse than 81.43% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Beryl Drugs's
Operating Income
for the
three
months ended in Mar. 2026 was ₹9.4 Mil. Beryl Drugs's Interest Expense for the
three
months ended in Mar. 2026 was ₹-0.7 Mil.
Beryl Drugs's interest coverage for the quarter that ended in Mar. 2026 was 13.11.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Beryl Drugs's Interest Coverage or its related term are showing as below:
BOM:524606'
s Interest Coverage Range Over the Past 10 Years
Min: 0.45 Med: 2.67 Max: 6.03
Current: 2.71
BOM:524606's Interest Coverage is ranked worse than 81.43% of 684
companies
in the Drug Manufacturers industry
Industry Median: 12.82
vs BOM:524606: 2.71
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Beryl Drugs Interest Coverage Related Terms
Beryl Drugs Interest Coverage Historical Data
* Premium members only.
The historical data trend for Beryl Drugs's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Drug Manufacturers - Specialty & Generic subindustry, Beryl Drugs's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beryl Drugs Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Beryl Drugs's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Beryl Drugs's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beryl Drugs (BOM:524606) has a Interest Coverage of 13.11 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Beryl Drugs and its competitors. This is 391% above median its historical median of 2.67. Over the past decade, Beryl Drugs' Interest Coverage has ranged from 0.45 to 6.03. According to the industry distribution chart, Beryl Drugs ranks #557 out of 684 companies in the Drug Manufacturers industry, placing it in the top 81.4%.
Is Beryl Drugs' Interest Coverage too high?
Beryl Drugs' current Interest Coverage of 13.11 is 391% above median its 10-year median of 2.67. Over the past 10 years, this metric has ranged from a low of 0.45 to a high of 6.03. The Drug Manufacturers industry median Interest Coverage is 12.82. Beryl Drugs' value of 13.11 is 2.3% above this industry median. Based on the distribution chart, Beryl Drugs ranks #557 out of 684 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Beryl Drugs has a GF Score™ of 68/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Beryl Drugs' Interest Coverage compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Beryl Drugs ranks #557 out of 684 companies for Interest Coverage. This places Beryl Drugs in the lower half of its industry. The industry median Interest Coverage is 12.82. Beryl Drugs' value of 13.11 is 2.3% above this benchmark. Historically, Beryl Drugs' own Interest Coverage has ranged from 0.45 to 6.03 over the past decade. While the company's 10-year median is 2.67 vs. the industry median of 12.82, Beryl Drugs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.82, based on 684 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beryl Drugs's current Interest Coverage of 13.11 is 2.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Beryl Drugs and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beryl Drugs's current Interest Coverage is 13.11, which is 391% above median its own 10-year median of 2.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beryl Drugs stock overvalued right now?
Based on GuruFocus' analysis, Beryl Drugs (BOM:524606) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹20.66, compared to a current price of ₹24.04 — trading 16.4% above its estimated fair value. The current Interest Coverage is 13.11, which is 391% above median its 10-year median of 2.67 and 2.3% above the Drug Manufacturers industry median of 12.82. Beryl Drugs' overall GF Score™ is 68/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Beryl Drugs (BOM:524606), the current Interest Coverage is 13.11 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beryl Drugs (BOM:524606) Overvalued in 2026?
Based on GuruFocus' analysis, Beryl Drugs stock appears to be overvalued.
The current stock price of ₹24.04 is trading 16.4% above its estimated GF Value™ of ₹20.66.
GuruFocus considers Beryl Drugs to be Modestly Overvalued.
Key valuation signals for BOM:524606:
Interest Coverage: 13.11 (391% above median its 10-year median of 2.67)
GF Value™: ₹20.66 vs. price of ₹24.04 (16.4% above fair value)
Industry Position: 2.3% above the Drug Manufacturers median (#557 of 684)
No single metric tells the full story. See the BOM:524606 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beryl Drugs Ltd is a pharmaceutical company principally engaged in the manufacturing and marketing of allopathic pharmaceutical preparations. It also provides contract manufacturing services and veterinary products. It offers manufacturing options for product requirements like small-volume injectables in liquid form, small-volume injectables in dry powder form, eye and ear drops, intravenous fluids in poly pack and glass bottles, and veterinary medicines. The company earns the majority of its revenue from the sale of Bulk Drugs.
68GF Score
Get the complete analysis for BOM:524606
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524606 has been successfully added to your 
